Eros Di Bona Sign in to save

OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (5)

4× UOC Oncoematologia, AULSS7 Pedemontana, Bassano del Grappa (VI), Vicenza, Italy
2× 10UOC Oncoematologia, AULSS7 Pedemontana, Bassano del Grappa (VI), Vicenza, Italy
1× King's College Hospital NHS, London, United Kingdom
1× 14UOC Oncoematologia, AULSS7 Pedemontana, Bassano del Grappa (VI), Italy
1× UOC Oncoematologia, AULSS7 Pedemontana Bassano del Grappa Vicenza Italy

Papers 8 stored

All · Aachen affiliation only

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy
2026 HemaSphere article Immunology and Microbiology Complement system in diseases Open access

0

citations
Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial
2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access

0

citations
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
2025 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access

15

citations
Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
2023 Blood conference-abstract Immunology and Microbiology Complement system in diseases

14

citations
MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
2023 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Complement system in diseases Open access

2

citations
POSTER: MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
2023 Clinical Lymphoma Myeloma & Leukemia article Immunology and Microbiology Complement system in diseases

0

citations
S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
2023 HemaSphere article Immunology and Microbiology Complement system in diseases Open access

2

citations
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
2022 Blood article Immunology and Microbiology Complement system in diseases

23

citations

8 results

Eros Di Bona ▲ Sign in to save

Departments & institutes in Aachen

Papers 8 stored

Eros Di Bona Sign in to save